_id
691aff1c3c536f8df23188a1
Ticker
SNW.XETRA
Name
Sanofi
Exchange
XETRA
Address
46, avenue de la Grande Armée, Paris, France, 75017
Country
Germany
Sector
Healthcare
Industry
Drug Manufacturers - General
Currency
EUR
Website
https://www.sanofi.com
Description
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Last Close
82.26
Volume
2769
Current Price
80.76
Change
0.9482129832239253
Last Updated
2025-12-30T12:23:05.099Z
Image
https://logo.clearbit.com/www.sanofi.com
Ipo Date
-
Market Cap
99648921600
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
13170000000
Cost Of Revenue
3412000000
Gross Profit
9758000000
Operating Expenses
6135000000
Operating Income
3623000000
Interest Expense
227000000
Pretax Income
3508000000
Net Income
2802000000
Eps
2.270848529054218
Dividends Per Share
-
Shares Outstanding
1211389666
Income Tax Expense
680000000
EBITDA
4214000000
Operating Margin
27.509491268033408
Total Other Income Expense Net
-115000000
Cash
8906000000
Short Term Investments
-
Receivables
497000000
Inventories
24501000000
Total Current Assets
34042000000
Property Plant Equipment
11181000000
Total Assets
129794000000
Payables
22000000000
Short Term Debt
8489000000
Long Term Debt
11700000000
Total Liabilities
56261000000
Equity
73263000000
Bs_currency_symbol
EUR
Depreciation
479000000
Change In Working Capital
-
Cash From Operations
3750000000
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
-1148000000
Net Change In Cash
-6453000000
Cf_currency_symbol
EUR
PE
15.6985
PB
1.3601649400106466
ROE
3.8245772081405347
ROA
2.158805491779281
FCF
3750000000
Fcf Percent
0.2847380410022779
Piotroski FScore
4
Health Score
70
Deep Value Investing Score
5.5
Defensive Investing Score
6
Dividend Investing Score
3
Economic Moat Investing Score
8.3
Garp Investing Score
5
Growth Investing Score
4.5
Momentum Investing Score
4
Net Net Investing Score
2.5
Quality Investing Score
8
Value Investing Score
6.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
13170000000
Quarters > 0 > income Statement > cost Of Revenue
3412000000
Quarters > 0 > income Statement > gross Profit
9758000000
Quarters > 0 > income Statement > operating Expenses
6135000000
Quarters > 0 > income Statement > operating Income
3623000000
Quarters > 0 > income Statement > interest Expense
227000000
Quarters > 0 > income Statement > pretax Income
3508000000
Quarters > 0 > income Statement > net Income
2802000000
Quarters > 0 > income Statement > eps
2.270848529054218
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
1233900000
Quarters > 0 > income Statement > income Tax Expense
680000000
Quarters > 0 > income Statement > EBITDA
4214000000
Quarters > 0 > income Statement > operating Margin
27.509491268033408
Quarters > 0 > income Statement > total Other Income Expense Net
-115000000
Quarters > 0 > income Statement > currency_symbol
EUR
Quarters > 0 > balance Sheet > cash
8906000000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
497000000
Quarters > 0 > balance Sheet > inventories
24501000000
Quarters > 0 > balance Sheet > total Current Assets
34042000000
Quarters > 0 > balance Sheet > property Plant Equipment
11181000000
Quarters > 0 > balance Sheet > total Assets
129794000000
Quarters > 0 > balance Sheet > payables
22000000000
Quarters > 0 > balance Sheet > short Term Debt
8489000000
Quarters > 0 > balance Sheet > long Term Debt
11700000000
Quarters > 0 > balance Sheet > total Liabilities
56261000000
Quarters > 0 > balance Sheet > equity
73263000000
Quarters > 0 > balance Sheet > currency_symbol
EUR
Quarters > 0 > cash Flow > net Income
2802000000
Quarters > 0 > cash Flow > depreciation
479000000
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
3750000000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-1148000000
Quarters > 0 > cash Flow > net Change In Cash
-6453000000
Quarters > 0 > cash Flow > currency_symbol
EUR
Quarters > 0 > ratios > PE
2.270848529054218
Quarters > 0 > ratios > PB
1.3601649400106466
Quarters > 0 > ratios > ROE
3.8245772081405347
Quarters > 0 > ratios > ROA
2.158805491779281
Quarters > 0 > ratios > FCF
3750000000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.2847380410022779
Quarters > 0 > health Score
70
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
10735000000
Quarters > 1 > income Statement > cost Of Revenue
2992000000
Quarters > 1 > income Statement > gross Profit
7743000000
Quarters > 1 > income Statement > operating Expenses
6269000000
Quarters > 1 > income Statement > operating Income
1474000000
Quarters > 1 > income Statement > interest Expense
216000000
Quarters > 1 > income Statement > pretax Income
1467000000
Quarters > 1 > income Statement > net Income
3940000000
Quarters > 1 > income Statement > eps
3.201430080442025
Quarters > 1 > income Statement > dividends Per Share
4772000000
Quarters > 1 > income Statement > shares Outstanding
1230700000
Quarters > 1 > income Statement > income Tax Expense
230000000
Quarters > 1 > income Statement > EBITDA
2690500000
Quarters > 1 > income Statement > operating Margin
13.730787144853284
Quarters > 1 > income Statement > total Other Income Expense Net
-7000000
Quarters > 1 > income Statement > currency_symbol
EUR
Quarters > 1 > balance Sheet > cash
15359000000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
8207000000
Quarters > 1 > balance Sheet > inventories
9618000000
Quarters > 1 > balance Sheet > total Current Assets
37017000000
Quarters > 1 > balance Sheet > property Plant Equipment
11007000000
Quarters > 1 > balance Sheet > total Assets
124959000000
Quarters > 1 > balance Sheet > payables
7075000000
Quarters > 1 > balance Sheet > short Term Debt
7561000000
Quarters > 1 > balance Sheet > long Term Debt
13200000000
Quarters > 1 > balance Sheet > total Liabilities
54680000000
Quarters > 1 > balance Sheet > equity
70008000000
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
2931000000
Quarters > 1 > cash Flow > depreciation
1801000000
Quarters > 1 > cash Flow > change In Working Capital
-613000000
Quarters > 1 > cash Flow > cash From Operations
3555000000
Quarters > 1 > cash Flow > capital Expenditures
1420000000
Quarters > 1 > cash Flow > cash From Investing
8727000000
Quarters > 1 > cash Flow > cash From Financing
-4489000000
Quarters > 1 > cash Flow > net Change In Cash
7918000000
Quarters > 1 > cash Flow > currency_symbol
EUR
Quarters > 1 > ratios > PE
3.201430080442025
Quarters > 1 > ratios > PB
1.4197139184093246
Quarters > 1 > ratios > ROE
5.627928236772941
Quarters > 1 > ratios > ROA
3.1530341952160303
Quarters > 1 > ratios > FCF
2135000000
Quarters > 1 > ratios > Piotroski FScore
3
Quarters > 1 > ratios > fcf Percent
0.19888216115510013
Quarters > 1 > health Score
72
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
10606000000
Quarters > 2 > income Statement > cost Of Revenue
2889000000
Quarters > 2 > income Statement > gross Profit
7717000000
Quarters > 2 > income Statement > operating Expenses
5432000000
Quarters > 2 > income Statement > operating Income
2285000000
Quarters > 2 > income Statement > interest Expense
213000000
Quarters > 2 > income Statement > pretax Income
2200000000
Quarters > 2 > income Statement > net Income
1872000000
Quarters > 2 > income Statement > eps
1.5171407731582787
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
1233900000
Quarters > 2 > income Statement > income Tax Expense
481000000
Quarters > 2 > income Statement > EBITDA
2902750000
Quarters > 2 > income Statement > operating Margin
21.544408825193287
Quarters > 2 > income Statement > total Other Income Expense Net
-85000000
Quarters > 2 > income Statement > currency_symbol
EUR
Quarters > 2 > balance Sheet > cash
7991000000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
447000000
Quarters > 2 > balance Sheet > inventories
21850000000
Quarters > 2 > balance Sheet > total Current Assets
44019000000
Quarters > 2 > balance Sheet > property Plant Equipment
11352000000
Quarters > 2 > balance Sheet > total Assets
131892000000
Quarters > 2 > balance Sheet > payables
21616000000
Quarters > 2 > balance Sheet > short Term Debt
7636000000
Quarters > 2 > balance Sheet > long Term Debt
11767000000
Quarters > 2 > balance Sheet > total Liabilities
57474000000
Quarters > 2 > balance Sheet > equity
74074000000
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
1872000000
Quarters > 2 > cash Flow > depreciation
698750000
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
2093000000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-776000000
Quarters > 2 > cash Flow > cash From Financing
-592000000
Quarters > 2 > cash Flow > net Change In Cash
705000000
Quarters > 2 > cash Flow > currency_symbol
EUR
Quarters > 2 > ratios > PE
1.5171407731582787
Quarters > 2 > ratios > PB
1.3452731592731595
Quarters > 2 > ratios > ROE
2.527202527202527
Quarters > 2 > ratios > ROA
1.4193430988990994
Quarters > 2 > ratios > FCF
2093000000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.19734112766358666
Quarters > 2 > health Score
68
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
11420000000
Quarters > 3 > income Statement > cost Of Revenue
3576000000
Quarters > 3 > income Statement > gross Profit
7844000000
Quarters > 3 > income Statement > operating Expenses
6659000000
Quarters > 3 > income Statement > operating Income
1185000000
Quarters > 3 > income Statement > interest Expense
289000000
Quarters > 3 > income Statement > pretax Income
1070000000
Quarters > 3 > income Statement > net Income
683000000
Quarters > 3 > income Statement > eps
0.5448308870453095
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
1253600000
Quarters > 3 > income Statement > income Tax Expense
190000000
Quarters > 3 > income Statement > EBITDA
2427500000
Quarters > 3 > income Statement > operating Margin
10.376532399299474
Quarters > 3 > income Statement > total Other Income Expense Net
-115000000
Quarters > 3 > income Statement > currency_symbol
EUR
Quarters > 3 > balance Sheet > cash
7441000000
Quarters > 3 > balance Sheet > short Term Investments
486000000
Quarters > 3 > balance Sheet > receivables
10629000000
Quarters > 3 > balance Sheet > inventories
9431000000
Quarters > 3 > balance Sheet > total Current Assets
42588000000
Quarters > 3 > balance Sheet > property Plant Equipment
11601000000
Quarters > 3 > balance Sheet > total Assets
132798000000
Quarters > 3 > balance Sheet > payables
7551000000
Quarters > 3 > balance Sheet > short Term Debt
4470000000
Quarters > 3 > balance Sheet > long Term Debt
11791000000
Quarters > 3 > balance Sheet > total Liabilities
54941000000
Quarters > 3 > balance Sheet > equity
77507000000
Quarters > 3 > balance Sheet > currency_symbol
EUR
Quarters > 3 > cash Flow > net Income
683000000
Quarters > 3 > cash Flow > depreciation
829500000
Quarters > 3 > cash Flow > change In Working Capital
2026000000
Quarters > 3 > cash Flow > cash From Operations
7658000000
Quarters > 3 > cash Flow > capital Expenditures
153000000
Quarters > 3 > cash Flow > cash From Investing
-994000000
Quarters > 3 > cash Flow > cash From Financing
-5852000000
Quarters > 3 > cash Flow > net Change In Cash
646000000
Quarters > 3 > cash Flow > currency_symbol
EUR
Quarters > 3 > ratios > PE
0.5448308870453095
Quarters > 3 > ratios > PB
1.3062140967912577
Quarters > 3 > ratios > ROE
0.8812107293534778
Quarters > 3 > ratios > ROA
0.5143149746231118
Quarters > 3 > ratios > FCF
7505000000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.6571803852889667
Quarters > 3 > health Score
67
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
44286000000
Annuals > 0 > income Statement > cost Of Revenue
13195000000
Annuals > 0 > income Statement > gross Profit
31091000000
Annuals > 0 > income Statement > operating Expenses
16641000000
Annuals > 0 > income Statement > operating Income
14450000000
Annuals > 0 > income Statement > interest Expense
596000000
Annuals > 0 > income Statement > pretax Income
6758000000
Annuals > 0 > income Statement > net Income
5560000000
Annuals > 0 > income Statement > eps
4.443023813329072
Annuals > 0 > income Statement > dividends Per Share
4704000000
Annuals > 0 > income Statement > shares Outstanding
1251400000
Annuals > 0 > income Statement > income Tax Expense
1204000000
Annuals > 0 > income Statement > EBITDA
11664000000
Annuals > 0 > income Statement > operating Margin
32.6288217495371
Annuals > 0 > income Statement > total Other Income Expense Net
-7692000000
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
7441000000
Annuals > 0 > balance Sheet > short Term Investments
486000000
Annuals > 0 > balance Sheet > receivables
10629000000
Annuals > 0 > balance Sheet > inventories
9431000000
Annuals > 0 > balance Sheet > total Current Assets
42588000000
Annuals > 0 > balance Sheet > property Plant Equipment
11601000000
Annuals > 0 > balance Sheet > total Assets
132798000000
Annuals > 0 > balance Sheet > payables
7551000000
Annuals > 0 > balance Sheet > short Term Debt
4470000000
Annuals > 0 > balance Sheet > long Term Debt
11791000000
Annuals > 0 > balance Sheet > total Liabilities
54941000000
Annuals > 0 > balance Sheet > equity
77507000000
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
5496000000
Annuals > 0 > cash Flow > depreciation
3586000000
Annuals > 0 > cash Flow > change In Working Capital
-615000000
Annuals > 0 > cash Flow > cash From Operations
9081000000
Annuals > 0 > cash Flow > capital Expenditures
3195000000
Annuals > 0 > cash Flow > cash From Investing
-4407000000
Annuals > 0 > cash Flow > cash From Financing
-5763000000
Annuals > 0 > cash Flow > net Change In Cash
-1269000000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
4.443023813329072
Annuals > 0 > ratios > PB
1.3375046898989769
Annuals > 0 > ratios > ROE
7.173545615234753
Annuals > 0 > ratios > ROA
4.186810042319915
Annuals > 0 > ratios > FCF
5886000000
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
0.13290881994309714
Annuals > 0 > health Score
68
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
41109000000
Annuals > 1 > income Statement > cost Of Revenue
12619000000
Annuals > 1 > income Statement > gross Profit
28490000000
Annuals > 1 > income Statement > operating Expenses
15510000000
Annuals > 1 > income Statement > operating Income
12980000000
Annuals > 1 > income Statement > interest Expense
522000000
Annuals > 1 > income Statement > pretax Income
6115000000
Annuals > 1 > income Statement > net Income
5400000000
Annuals > 1 > income Statement > eps
4.2979942693409745
Annuals > 1 > income Statement > dividends Per Share
4454000000
Annuals > 1 > income Statement > shares Outstanding
1256400000
Annuals > 1 > income Statement > income Tax Expense
1017000000
Annuals > 1 > income Statement > EBITDA
11076000000
Annuals > 1 > income Statement > operating Margin
31.574594371062297
Annuals > 1 > income Statement > total Other Income Expense Net
-6865000000
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
8710000000
Annuals > 1 > balance Sheet > short Term Investments
270000000
Annuals > 1 > balance Sheet > receivables
11040000000
Annuals > 1 > balance Sheet > inventories
9666000000
Annuals > 1 > balance Sheet > total Current Assets
30670000000
Annuals > 1 > balance Sheet > property Plant Equipment
11814000000
Annuals > 1 > balance Sheet > total Assets
126464000000
Annuals > 1 > balance Sheet > payables
7328000000
Annuals > 1 > balance Sheet > short Term Debt
2320000000
Annuals > 1 > balance Sheet > long Term Debt
14347000000
Annuals > 1 > balance Sheet > total Liabilities
52111000000
Annuals > 1 > balance Sheet > equity
74040000000
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
5062000000
Annuals > 1 > cash Flow > depreciation
4429000000
Annuals > 1 > cash Flow > change In Working Capital
413000000
Annuals > 1 > cash Flow > cash From Operations
10258000000
Annuals > 1 > cash Flow > capital Expenditures
1619000000
Annuals > 1 > cash Flow > cash From Investing
-6200000000
Annuals > 1 > cash Flow > cash From Financing
-8052000000
Annuals > 1 > cash Flow > net Change In Cash
-4026000000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
4.2979942693409745
Annuals > 1 > ratios > PB
1.4057290113452188
Annuals > 1 > ratios > ROE
7.293354943273905
Annuals > 1 > ratios > ROA
4.26998987854251
Annuals > 1 > ratios > FCF
8639000000
Annuals > 1 > ratios > Piotroski FScore
3
Annuals > 1 > ratios > fcf Percent
0.21014862925393465
Annuals > 1 > health Score
74
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
40304000000
Annuals > 2 > income Statement > cost Of Revenue
11869000000
Annuals > 2 > income Statement > gross Profit
28435000000
Annuals > 2 > income Statement > operating Expenses
15286000000
Annuals > 2 > income Statement > operating Income
13149000000
Annuals > 2 > income Statement > interest Expense
394000000
Annuals > 2 > income Statement > pretax Income
9992000000
Annuals > 2 > income Statement > net Income
8371000000
Annuals > 2 > income Statement > eps
6.686636312804537
Annuals > 2 > income Statement > dividends Per Share
4168000000
Annuals > 2 > income Statement > shares Outstanding
1251900000
Annuals > 2 > income Statement > income Tax Expense
1909000000
Annuals > 2 > income Statement > EBITDA
13093000000
Annuals > 2 > income Statement > operating Margin
32.62455339420405
Annuals > 2 > income Statement > total Other Income Expense Net
-3157000000
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
12736000000
Annuals > 2 > balance Sheet > short Term Investments
663000000
Annuals > 2 > balance Sheet > receivables
10746000000
Annuals > 2 > balance Sheet > inventories
8960000000
Annuals > 2 > balance Sheet > total Current Assets
34110000000
Annuals > 2 > balance Sheet > property Plant Equipment
11684000000
Annuals > 2 > balance Sheet > total Assets
126722000000
Annuals > 2 > balance Sheet > payables
6813000000
Annuals > 2 > balance Sheet > short Term Debt
4451000000
Annuals > 2 > balance Sheet > long Term Debt
14857000000
Annuals > 2 > balance Sheet > total Liabilities
51570000000
Annuals > 2 > balance Sheet > equity
74784000000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
8371000000
Annuals > 2 > cash Flow > depreciation
3420000000
Annuals > 2 > cash Flow > change In Working Capital
-707000000
Annuals > 2 > cash Flow > cash From Operations
10526000000
Annuals > 2 > cash Flow > capital Expenditures
2201000000
Annuals > 2 > cash Flow > cash From Investing
-2075000000
Annuals > 2 > cash Flow > cash From Financing
-5821000000
Annuals > 2 > cash Flow > net Change In Cash
2638000000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
6.686636312804537
Annuals > 2 > ratios > PB
1.3867591463414635
Annuals > 2 > ratios > ROE
11.19357081728712
Annuals > 2 > ratios > ROA
6.605798519594072
Annuals > 2 > ratios > FCF
8325000000
Annuals > 2 > ratios > Piotroski FScore
3
Annuals > 2 > ratios > fcf Percent
0.20655518062723302
Annuals > 2 > health Score
79
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
39175000000
Annuals > 3 > income Statement > cost Of Revenue
12251000000
Annuals > 3 > income Statement > gross Profit
26924000000
Annuals > 3 > income Statement > operating Expenses
18798000000
Annuals > 3 > income Statement > operating Income
8126000000
Annuals > 3 > income Statement > interest Expense
362000000
Annuals > 3 > income Statement > pretax Income
7837000000
Annuals > 3 > income Statement > net Income
6223000000
Annuals > 3 > income Statement > eps
4.968463073852296
Annuals > 3 > income Statement > dividends Per Share
4008000000
Annuals > 3 > income Statement > shares Outstanding
1252500000
Annuals > 3 > income Statement > income Tax Expense
1558000000
Annuals > 3 > income Statement > EBITDA
11251000000
Annuals > 3 > income Statement > operating Margin
20.742820676451817
Annuals > 3 > income Statement > total Other Income Expense Net
-289000000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
10098000000
Annuals > 3 > balance Sheet > short Term Investments
1054000000
Annuals > 3 > balance Sheet > receivables
9787000000
Annuals > 3 > balance Sheet > inventories
8715000000
Annuals > 3 > balance Sheet > total Current Assets
30653000000
Annuals > 3 > balance Sheet > property Plant Equipment
11976000000
Annuals > 3 > balance Sheet > total Assets
120242000000
Annuals > 3 > balance Sheet > payables
6180000000
Annuals > 3 > balance Sheet > short Term Debt
3452000000
Annuals > 3 > balance Sheet > long Term Debt
17123000000
Annuals > 3 > balance Sheet > total Liabilities
51211000000
Annuals > 3 > balance Sheet > equity
68681000000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
6223000000
Annuals > 3 > cash Flow > depreciation
3351000000
Annuals > 3 > cash Flow > change In Working Capital
1409000000
Annuals > 3 > cash Flow > cash From Operations
10522000000
Annuals > 3 > cash Flow > capital Expenditures
2043000000
Annuals > 3 > cash Flow > cash From Investing
-7298000000
Annuals > 3 > cash Flow > cash From Financing
-7056000000
Annuals > 3 > cash Flow > net Change In Cash
-3817000000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
4.968463073852296
Annuals > 3 > ratios > PB
1.5107103856961897
Annuals > 3 > ratios > ROE
9.060730041787394
Annuals > 3 > ratios > ROA
5.175396284160277
Annuals > 3 > ratios > FCF
8479000000
Annuals > 3 > ratios > Piotroski FScore
3
Annuals > 3 > ratios > fcf Percent
0.21643905552010212
Annuals > 3 > health Score
76
Valuation > metrics > PE
15.6985
Valuation > metrics > PB
1.3601649400106466
Valuation > final Score
100
Valuation > verdict
Fair
Profitability > metrics > ROE
3.8245772081405347
Profitability > metrics > ROA
8.231008753892251
Profitability > metrics > Net Margin
0.21275626423690205
Profitability > final Score
62
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
0.7679319711177538
Risk > metrics > Interest Coverage
15.960352422907489
Risk > final Score
88
Risk > verdict
Low
Liquidity > metrics > Current Ratio
1.1165338318737905
Liquidity > metrics > Quick Ratio
0.31293253304470464
Liquidity > final Score
44
Liquidity > verdict
Weak
Prev Valuations > 0
100
Prev Valuations > 1
100
Prev Valuations > 2
100
Prev Profitabilities > 0
71
Prev Profitabilities > 1
44
Prev Profitabilities > 2
16
Prev Risks > 0
75
Prev Risks > 1
88
Prev Risks > 2
64
Prev Liquidities > 0
100
Prev Liquidities > 1
76
Prev Liquidities > 2
100
Updated At
2026-01-20T23:07:56.500Z
Earnings History > 0 > period
2026-03-31
Earnings History > 0 > report Date
2026-04-22
Earnings History > 0 > date
2026-03-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-12-31
Earnings History > 1 > report Date
2026-01-29
Earnings History > 1 > date
2025-12-31
Earnings History > 1 > before After Market
AfterMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-
Earnings History > 1 > eps Estimate
1.44
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2024-09-30
Earnings History > 2 > report Date
2024-10-25
Earnings History > 2 > date
2024-09-30
Earnings History > 2 > before After Market
BeforeMarket
Earnings History > 2 > currency
EUR
Earnings History > 2 > eps Actual
2.86
Earnings History > 2 > eps Estimate
2.48
Earnings History > 2 > eps Difference
0.38
Earnings History > 2 > surprise Percent
15.3226
Earnings History > 3 > period
2023-09-30
Earnings History > 3 > report Date
2023-10-27
Earnings History > 3 > date
2023-09-30
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
EUR
Earnings History > 3 > eps Actual
2.55
Earnings History > 3 > eps Estimate
2.61
Earnings History > 3 > eps Difference
-0.06
Earnings History > 3 > surprise Percent
-2.2989
Earnings History > 4 > period
2023-06-30
Earnings History > 4 > report Date
2023-07-28
Earnings History > 4 > date
2023-06-30
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
EUR
Earnings History > 4 > eps Actual
1.74
Earnings History > 4 > eps Estimate
1.63
Earnings History > 4 > eps Difference
0.11
Earnings History > 4 > surprise Percent
6.7485
Earnings History > 5 > period
2023-03-31
Earnings History > 5 > report Date
2023-04-27
Earnings History > 5 > date
2023-03-31
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
EUR
Earnings History > 5 > eps Actual
2.16
Earnings History > 5 > eps Estimate
2.01
Earnings History > 5 > eps Difference
0.15
Earnings History > 5 > surprise Percent
7.4627
Earnings History > 6 > period
2021-06-30
Earnings History > 6 > report Date
2021-06-30
Earnings History > 6 > date
2021-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
EUR
Earnings History > 6 > eps Actual
1.38
Earnings History > 6 > eps Estimate
1.32
Earnings History > 6 > eps Difference
0.06
Earnings History > 6 > surprise Percent
4.5455
Earnings History > 7 > period
2018-09-30
Earnings History > 7 > report Date
2018-09-30
Earnings History > 7 > date
2018-09-30
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
EUR
Earnings History > 7 > eps Actual
1.84
Earnings History > 7 > eps Estimate
1.73
Earnings History > 7 > eps Difference
0.11
Earnings History > 7 > surprise Percent
6.3584
Earnings History > 8 > period
2018-06-30
Earnings History > 8 > report Date
2018-06-30
Earnings History > 8 > date
2018-06-30
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
EUR
Earnings History > 8 > eps Actual
1.25
Earnings History > 8 > eps Estimate
1.23
Earnings History > 8 > eps Difference
0.02
Earnings History > 8 > surprise Percent
1.626
Earnings History > 9 > period
2018-03-31
Earnings History > 9 > report Date
2018-03-31
Earnings History > 9 > date
2018-03-31
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
EUR
Earnings History > 9 > eps Actual
1.28
Earnings History > 9 > eps Estimate
1.14
Earnings History > 9 > eps Difference
0.14
Earnings History > 9 > surprise Percent
12.2807
Earnings History > 10 > period
2017-12-31
Earnings History > 10 > report Date
2017-12-31
Earnings History > 10 > date
2017-12-31
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
EUR
Earnings History > 10 > eps Actual
1.06
Earnings History > 10 > eps Estimate
1.15
Earnings History > 10 > eps Difference
-0.09
Earnings History > 10 > surprise Percent
-7.8261
Earnings History > 11 > period
2017-09-30
Earnings History > 11 > report Date
2017-09-30
Earnings History > 11 > date
2017-09-30
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
EUR
Earnings History > 11 > eps Actual
1.71
Earnings History > 11 > eps Estimate
1.72
Earnings History > 11 > eps Difference
-0.01
Earnings History > 11 > surprise Percent
-0.5814
Earnings History > 12 > period
2017-06-30
Earnings History > 12 > report Date
2017-06-30
Earnings History > 12 > date
2017-06-30
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
EUR
Earnings History > 12 > eps Actual
1.35
Earnings History > 12 > eps Estimate
1.29
Earnings History > 12 > eps Difference
0.06
Earnings History > 12 > surprise Percent
4.6512
Earnings History > 13 > period
2017-03-31
Earnings History > 13 > report Date
2017-03-31
Earnings History > 13 > date
2017-03-31
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
EUR
Earnings History > 13 > eps Actual
1.42
Earnings History > 13 > eps Estimate
1.27
Earnings History > 13 > eps Difference
0.15
Earnings History > 13 > surprise Percent
11.811
Earnings History > 14 > period
2015-09-30
Earnings History > 14 > report Date
2015-09-30
Earnings History > 14 > date
2015-09-30
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
EUR
Earnings History > 14 > eps Actual
1.247
Earnings History > 14 > eps Estimate
-
Earnings History > 14 > eps Difference
0
Earnings History > 14 > surprise Percent
-
Earnings History > 15 > period
2015-06-30
Earnings History > 15 > report Date
2015-06-30
Earnings History > 15 > date
2015-06-30
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
EUR
Earnings History > 15 > eps Actual
0.997
Earnings History > 15 > eps Estimate
-
Earnings History > 15 > eps Difference
0
Earnings History > 15 > surprise Percent
-
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Stock Price
€0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Sanofi
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
1.44
Date
2024-09-30
EPS Actual
2.86
EPS Estimate
2.48
EPS Difference
0.38
Surprise Percent
15.3226%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2025-09-30)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.